Skip to main content
SpringerLink
Log in

New safety information for rituximab

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Hoffmann-La Roche Limited.Association of RITUXAN (Rm) (rituximab) with Progressive Multifocal Leukoencephalopathy (PML) in patients with Systemic Lupus Erythematosus (SLE) and vasculitis. Media Release: 8 Aug 2007. Available from: URL: http://www.hc-sc.gc.ca

  2. Hoffmann-La Roche Limited.Reports of progressive multifocal leukoencephalopathy (PML) following RITUXAN use in systemic lupus erythematosus and vasculitis (off-label use). Internet Document: [3 pages], 8 Aug 2007. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

New safety information for rituximab. React. Wkly. 1165, 3 (2007). https://doi.org/10.2165/00128415-200711650-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711650-00005

Keywords

Search

Navigation